Memorial Sloan Kettering Cancer Center Presents Ovarian Cancer Trial Results
What happened
A late-breaking oral presentation was given at ENA 2026 in Barcelona by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center. The presentation detailed results for Rezatapopt in patients with platinum-resistant or refractory ovarian cancer. In the primary analysis population of 65 patients, the overall response rate was 48%, with a median duration of response of 10.4 months. Across all cohorts of 168 evaluable patients, the overall response rate was 36% and the median duration of response was 8.1 months.
From manilatimes.net
Why it matters
The study results support the planned submission of the Rezatapopt New Drug Application in the first quarter of 2027. Memorial Sloan Kettering Cancer Center maintains a clinical trial partnership with Novartis, which is involved in the research and development of cancer treatments.
From manilatimes.net
Who's involved
- Memorial Sloan Kettering Cancer CenterCancer treatment and research institution that presented the trial results.
- NovartisPharmaceutical corporation with a clinical trial partnership with Memorial Sloan Kettering Cancer Center.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NovartisSpeculative
Novartis might see changes in revenue or investment based on the regulatory pathway and market acceptance of Rezatapopt.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- MSKCC's successful cancer trial may increase competitive pressure on Mayo ClinicMSKCC's successful cancer trial may increase competitive pressure on Mayo Clinic.Possible
- Positive data on Rezatapopt may boost Novartis's research potentialPositive clinical data on Rezatapopt may boost Novartis's research collaboration potentialPossible
Keep exploring
The entities involved
-
Memorial Sloan Kettering Cancer Center
cancer treatment and research institution in New York City, United States
-
Barcelona
city in Catalonia, Spain